Zogenix To Pay $250m Upfront To Buy Modis For Ultra-Orphan Drug
The takeover will diversify Zogenix’s pipeline through the addition of MT1621, a drug that improved the probability of survival in patients with an inherited mitochondrial DNA depletion disorder.
You may also be interested in...
Bristol-Myers Squibb will partner with the biotech accelerator to fund and launch biotechs, with the pharma getting an option to buy. Novartis signs another agreement with IFM months after buying its IFM Tre affiliate.
The approval is based on the results ABRE clinical study, which showed the stent improved patency iliofemoral veins in 88% of cases with a 2% rate of major adverse events.
Reporting its first full quarter of financials since merging with Allergan, AbbVie will be scrutinized for whether its optimistic talk of a quick Botox rebound actually happened.